Lista de obras - Lukasz Skalniak - Dominio Público Uruguay

1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.

artículo científico publicado en 2017

A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells

artículo científico publicado en 2019

A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018)

scientific article published on 01 March 2019

Application of bioorthogonal hetero-Diels–Alder cycloaddition of 5-arylidene derivatives of 1,3-dimethylbarbituric acid and vinyl thioether for imaging inside living cells

artículo científico publicado en 2021

Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

artículo científico publicado en 2017

Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

artículo científico publicado en 2022

CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?

artículo científico publicado en 2019

CA-170 – a potent small-molecule PD-L1 inhibitor or not?

artículo científico publicado en 2019

Conserved conformational changes in the ATPase cycle of human Hsp90.

artículo científico publicado en 2008

Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction

scientific article published on 25 July 2019

Di-Bromo-based small-molecule inhibitors of the PD-1/PD-L1 immune checkpoint

scientific article published on 16 September 2020

Effect of silver nanoparticles on human primary keratinocytes

artículo científico publicado en 2013

Effects of the novel mitochondrial protein mimitin in insulin-secreting cells

artículo científico publicado en 2012

Effects triggered by platinum nanoparticles on primary keratinocytes.

artículo científico publicado en 2013

Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists

artículo científico publicado en 2019

Human and mouse PD-L1: similar molecular structure, but different druggability profiles

artículo científico publicado en 2021

Identification of small-molecule inhibitors of USP2a

artículo científico publicado en 2018

Limited GADD45α expression and function in IL-1β toxicity towards insulin-producing cells

artículo científico publicado en 2013

Lithocholic Acid Hydroxyamide Destabilizes Cyclin D1 and Induces G0/G1 Arrest by Inhibiting Deubiquitinase USP2a

artículo científico publicado en 2017

MCPIP1 contributes to the inflammatory response of UVB-treated keratinocytes.

artículo científico publicado en 2017

MCPIP1 contributes to the toxicity of proteasome inhibitor MG-132 in HeLa cells by the inhibition of NF-κB

artículo científico publicado en 2014

Macrocyclic Peptide Inhibitor of PD‐1/PD‐L1 Immune Checkpoint

artículo científico publicado en 2020

Monocyte chemotactic protein-1-induced protein-1 (MCPIP1) is a novel multifunctional modulator of inflammatory reactions

artículo científico publicado en 2012

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action

artículo científico publicado en 2021

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells

article

Proteasome inhibitor MG-132 induces MCPIP1 expression

artículo científico publicado en 2013

Regulatory feedback loop between NF-kappaB and MCP-1-induced protein 1 RNase

artículo científico publicado en 2009

Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.

artículo científico publicado en 2017

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells.

artículo científico publicado en 2017

Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction

artículo científico publicado en 2021

Terphenyl-based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein−Protein Interaction

artículo científico publicado en 2021

Terphenyl-based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein−Protein Interaction

artículo científico publicado en 2021

p38 but not p53 is responsible for UVA-induced MCPIP1 expression

artículo científico publicado en 2017

Lista de obras de Lukasz Skalniak

1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.

A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells

A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018)

Application of bioorthogonal hetero-Diels–Alder cycloaddition of 5-arylidene derivatives of 1,3-dimethylbarbituric acid and vinyl thioether for imaging inside living cells

Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint.

Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?

CA-170 – a potent small-molecule PD-L1 inhibitor or not?

Conserved conformational changes in the ATPase cycle of human Hsp90.

Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction

Di-Bromo-based small-molecule inhibitors of the PD-1/PD-L1 immune checkpoint

Effect of silver nanoparticles on human primary keratinocytes

Effects of the novel mitochondrial protein mimitin in insulin-secreting cells

Effects triggered by platinum nanoparticles on primary keratinocytes.

Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists

Human and mouse PD-L1: similar molecular structure, but different druggability profiles

Identification of small-molecule inhibitors of USP2a

Limited GADD45α expression and function in IL-1β toxicity towards insulin-producing cells

Lithocholic Acid Hydroxyamide Destabilizes Cyclin D1 and Induces G0/G1 Arrest by Inhibiting Deubiquitinase USP2a

MCPIP1 contributes to the inflammatory response of UVB-treated keratinocytes.

MCPIP1 contributes to the toxicity of proteasome inhibitor MG-132 in HeLa cells by the inhibition of NF-κB

Macrocyclic Peptide Inhibitor of PD‐1/PD‐L1 Immune Checkpoint

Monocyte chemotactic protein-1-induced protein-1 (MCPIP1) is a novel multifunctional modulator of inflammatory reactions

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells

Proteasome inhibitor MG-132 induces MCPIP1 expression

Regulatory feedback loop between NF-kappaB and MCP-1-induced protein 1 RNase

Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells.

Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction

Terphenyl-based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein−Protein Interaction

Terphenyl-based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein−Protein Interaction

p38 but not p53 is responsible for UVA-induced MCPIP1 expression